Severe sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorin

Journal of Clinical Oncology

Volumn 26, Issue 20, 2008, Pages 3411-3417

  Hennig, Ivo M ^a   Naik, Jay D ^a   Brown, Sarah ^a   Szubert, Alex ^a   Anthoney, David A ^a   Jackson, David P ^a   Melcher, Alan M ^a   Crawford, S Michael ^a   Bradley, Christopher ^a   Brown, Julia M B ^a   Seymour, Matthew T ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HUMAN; INTESTINE CANCER; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COLON RESECTION; COLORECTAL TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG INTERACTION; FOLLOW UP; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROSPECTIVE STUDY; REFERENCE VALUE; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49149105718     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.9426     Document Type: Article

References (35)

1. Francini G, Petrioli R, Lorenzini L, et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106:899-906, 1994
2. O'Connell M: A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluorouracil (FU) for the treatment of advanced colorectal cancer: Experience of the Mayo Clinic and North Central Cancer Treatment Group. Adv Exp Med Biol 244:173-184, 1988
3. Wolmark N, Bryant J, Smith R, et al: Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 90:1810-1816, 1998
4. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999
5. Andre T, Colin P, Louvet C, et al: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 21:2896-2903, 2003
6. Arkenau H, Bermann A, Rettig K, et al: 5-fluorocuracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: Long-term follow-up results of the adjCCA-01 trial. Ann Oncol 14:395-399, 2003
7. Saini A, Norman AR, Cunningham D, et al: Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88:1859-1865, 2003
8. Poplin EA, Benedetti JK, Estes NC, et al: Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23:1819-1825, 2005
9. Haller DG, Catalano PJ, Macdonald JS, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005
10. QUASAR Collaborative Group: Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. Lancet 355:1588-1596, 2000
11. Patel K, Anthoney D, Crellin A, et al: Weekly 5-fluorouracil and leucovorin: Achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 15:568-573, 2004
12. Liu G, Franssen E, Fitch M, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997
13. Borner MM, Schoffski P, de Wit R, et al: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349-358, 2002
14. Scheithauer W, McKendrick J, Begbie S, et al: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 14:1735-1743, 2003
15. Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704, 2005
16. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
17. O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300, 1998
18. Tomiak A, Vincent M, Kocha W, et al: Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: Prohibitive toxicity? Am J Clin Oncol 23:94-98, 2000
19. Twelves C, Gollins S, Grieve R, et al: A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17:239-245, 2006
20. Ward SE, Kaltenthaler E, Cowan J, et al: The clinical and economical benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 95:27-34, 2006
21. Pfeiffer P, Mortensen JP, Bjerregaard B, et al: Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 42:2738-2743, 2006
22. Cassidy J, Dirix L, Bissett D, et al: A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 4:2755-2761, 1998
23. Budman DR, Meropol NJ, Reigner B, et al: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 16:1795-1802, 1998
24. Mackean M, Planting A, Twelves C, et al: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985, 1998
25. Hansen R, Beatty P, Quebbeman E, et al: A phase I trial of protracted 5-fluorouracil infusion an oral calcium leucovorin. Cancer Invest 11:247-251, 1993
26. Allegra C, Chabner B, Drake J, et al: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720-9726, 1985
27. Radparvar S, Houghton P, Houghton J: Characteristics of thymidylate synthase purified from a human colon adenocarcinoma. Arch Biochem Biophys 260:342-350, 1988
28. Radparvar S, Houghton P, Houghton J: Effect of polyglutamation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′- deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 38:335-342, 1989
29. Romanini A, Lin J, Niedzwiecki D, et al: Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 51:789-793, 1991
30. Boarman D, Allegra C: Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res 52:36-44, 1992
31. Houghton J, Williams L, Cheshire P, et al: Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorocuracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res 50:3940-3946, 1990
32. Houghton JA, Williams LG, de Graaf SS, et al: Relationship between dose rate of [6RS]leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetra-hydrofolates in human colon adenocarcinoma xenografts. Cancer Res 50:3493-3502, 1990
33. Houghton JA, Williams LG, Loftin SK, et al: Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 30:423-432, 1992
34. Grogan L, Sotos GA, Allegra CJ: Leucovorin modulation of fluorouracil. Oncology (Williston Park) 7:63-72, 1993
35. Haller DG, Cassidy J, Clarke S, et al: Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol 24:149s, 2006 (suppl; abstr 3514).